Royal Bank Of Canada Mirati Therapeutics, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $1.57 Million - $2.34 Million	-37,433 Reduced 62.12%	22,831 $1.34 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $358,898 - $585,468	12,910 Added 27.26%	60,264 $2.63 Million
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $87,001 - $119,171	-2,408 Reduced 4.84%	47,354 $1.71 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $672,701 - $998,926	18,410 Added 58.72%	49,762 $1.85 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $199,788 - $477,419	4,841 Added 18.26%	31,352 $1.42 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $133,161 - $194,034	2,238 Added 9.22%	26,511 $1.85 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $427,627 - $968,713	10,920 Added 81.78%	24,273 $1.63 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $3.44 Million - $6.85 Million	-45,392 Reduced 77.27%	13,353 $1.1 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $6.52 Million - $9.4 Million	49,390 Added 527.95%	58,745 $8.62 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $1.68 Million - $2.26 Million	-12,712 Reduced 57.61%	9,355 $1.66 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $3.18 Million - $3.97 Million	22,067 New	22,067 $3.57 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.